<DOC>
	<DOCNO>NCT00301366</DOCNO>
	<brief_summary>The purpose clinical study ass safety tolerability Alpha-1 MP adult Alpha1-antitrypsin deficient patient .</brief_summary>
	<brief_title>The Safety Tolerability Alpha-1 Modified Process ( MP ) In Subjects With Alpha-1-antitrypsin ( AAT ) Deficiency</brief_title>
	<detailed_description>The objective clinical trial ( STAMP : Safety Tolerability Alpha-1 Modified Process ) study safety tolerability Alpha-1 MP adult Alpha 1-antitrypsin deficient subject report 20 week therapy . The primary objective describe nature frequency treatment-emergent adverse event `` treatment-emergent '' define adverse event occur start first study drug infusion .</detailed_description>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Documented diagnosis congenital Alpha1antitrypsin deficiency Documented force expiratory volume 1 second ( FEV1 ) 20 % 80 % predict value within last 6 month . Signed write informed consent prior initiation study related procedure . Females pregnant , breast feeding , childbearing potential , unwilling practice adequate contraception throughout study Use systemic steroid within 2 week prior receive study treatment ( include use inhaled steroid use routine need basis ) . Subjects exacerbation disease within one month trial entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>alpha 1-Antitrypsin Deficiency</keyword>
	<keyword>alpha 1-Antitrypsin</keyword>
	<keyword>pulmonary emphysema</keyword>
</DOC>